503469-17-8

Basic information

• Product Name: Methanesulfonic acid, trifluoro-, 2-hydroxy-3-[3-(4-morpholinyl)-1,3-dioxopropyl]phenyl ester
• CAS NO: 503469-17-8
• Molecular Formula: C14H14F3NO7S
• Molecular Weight: 397.329
• Mol File: 503469-17-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Methanesulfonic acid, trifluoro-, 2-hydroxy-3-[3-(4-morpholinyl)-1,3-dioxopropyl]phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid, trifluoro-, 2-hydroxy-3-[3-(4-morpholinyl)-1,3-dioxopropyl]phenyl ester(503469-17-8)
• EPA Substance Registry System: Methanesulfonic acid, trifluoro-, 2-hydroxy-3-[3-(4-morpholinyl)-1,3-dioxopropyl]phenyl ester(503469-17-8)

Safety Data

• Hazardous Substances Data: 503469-17-8(Hazardous Substances Data)

Upstream product

• 303-38-8 2,3-Dihydroxybenzoic acid 
• 2411-83-8 methyl-2,3-dihydroxybenzoate 
• 15159-40-7 4-morpholinocarbonyl chloride 
• 1696-20-4 4-acetylmorpholine 
• 351002-09-0 2-hydroxy-3-trifluoromethanesulfonyloxybenzoic acid methyl ester 

Relevant articles and documents

Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug

The phosphatidylinositol-3-kinase/Akt (PI3K/Akt) pathway is constitutively activated in a substantial proportion of prostate tumors and is considered a key mechanism supporting progression toward an androgen-independent status, for which no effective therapy is available. Therefore, PI3K inhibitors, alone or in combination with other cytotoxic drugs, could potentially be used to treat cancer with a constitutive activated PI3K/Akt pathway. To selectively target advanced prostate tumors with a constitutive activated PI3K/Akt pathway, a prostate cancer-specific PI3K inhibitor was generated by coupling the chemically modified form of the quercetin analogue LY294002 (HO-CH2-LY294002, compound 8) with the peptide Mu-LEHSSKLQL, in which the internal sequence HSSKLQ is a substrate for the prostate-specific antigen (PSA) protease. The result is a water-soluble and latent PI3K inhibitor prodrug (compound 11), its activation being dependent on PSA cleavage. Once activated, the L-O-CH2-LY294002 (compound 10) can specifically inhibit PI3K in PSA-secreting prostate cancer cells and induce apoptosis with a potency comparable to that of the original LY294002 compound.

PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues

Synthetic 2-morpholinochromones, including the known PI3-kinase inhibitor LY294002, have been evaluated in vitro as inhibitors of isolated human platelet phosphodiesterases. Inhibition of the cAMP-phosphodiesterases, PDE2 and PDE3 by LY294002 is reported

Synthetic studies of the phosphatidylinositol 3-kinase inhibitor LY294002 and related analogues

Synthetic methodologies have been developed for the direct and high-yielding preparation of the phosphatidyl-inositol 3-kinase inhibitor LY294002. These methods are readily amenable to the efficient generation of analogues, which will facilitate a detailed investigation of this important family of enzymes.